These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18657665)

  • 1. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.
    Setoguchi S; Schneeweiss S; Avorn J; Katz JN; Weinblatt ME; Levin R; Solomon DH
    Am Heart J; 2008 Aug; 156(2):336-41. PubMed ID: 18657665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.
    Solomon DH; Rassen JA; Kuriya B; Chen L; Harrold LR; Graham DJ; Lewis JD; Lii J; Liu L; Griffin MR; Curtis JR
    Ann Rheum Dis; 2013 Nov; 72(11):1813-8. PubMed ID: 23155221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
    Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
    Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
    Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
    Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.
    Solomon DH; Curtis JR; Saag KG; Lii J; Chen L; Harrold LR; Herrinton LJ; Graham DJ; Kowal MK; Kuriya B; Liu L; Griffin MR; Lewis JD; Rassen JA
    Am J Med; 2013 Aug; 126(8):730.e9-730.e17. PubMed ID: 23885678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.
    Curtis JR; Kramer JM; Martin C; Saag KG; Patkar N; Shatin D; Burgess M; Xie A; Braun MM
    Rheumatology (Oxford); 2007 Nov; 46(11):1688-93. PubMed ID: 17938138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
    Cacciapaglia F; Navarini L; Menna P; Salvatorelli E; Minotti G; Afeltra A
    Autoimmun Rev; 2011 Aug; 10(10):631-5. PubMed ID: 21539939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
    Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
    Johnson TM; Sayles HR; Baker JF; George MD; Roul P; Zheng C; Sauer B; Liao KP; Anderson DR; Mikuls TR; England BR
    Ann Rheum Dis; 2021 Nov; 80(11):1385-1392. PubMed ID: 34049859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of rheumatoid arthritis disease characteristics on heart failure.
    Myasoedova E; Crowson CS; Nicola PJ; Maradit-Kremers H; Davis JM; Roger VL; Therneau TM; Gabriel SE
    J Rheumatol; 2011 Aug; 38(8):1601-6. PubMed ID: 21572155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis.
    Lane MA; McDonald JR; Zeringue AL; Caplan L; Curtis JR; Ranganathan P; Eisen SA
    Medicine (Baltimore); 2011 Mar; 90(2):139-145. PubMed ID: 21358439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Heart Failure in Rheumatoid Arthritis Patients Treated with Tumor Necrosis Factor-α Inhibitors.
    Chen HK; Shao SC; Weng MY; Lin SJ; Hung MJ; Chan YY; Lai EC
    Clin Pharmacol Ther; 2021 Dec; 110(6):1595-1603. PubMed ID: 34496051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
    Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
    Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.
    Greenberg JD; Reed G; Kremer JM; Tindall E; Kavanaugh A; Zheng C; Bishai W; Hochberg MC;
    Ann Rheum Dis; 2010 Feb; 69(2):380-6. PubMed ID: 19359261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
    Wolfe F; Caplan L; Michaud K
    Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice].
    La Montagna G; Tirri R; Vitello R; Malesci D; Buono R; Mennillo G; Valentini G
    Reumatismo; 2006; 58(4):261-7. PubMed ID: 17216014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.